Eris Lifesciences approves acquiring the remaining 30% stake in Swiss Parenterals and plans a preferential equity issue to settle consideration, with a postal ballot for related-party transaction.
AI Assistant
ERIS Lifesciences Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.